Lupin Limited has informed the Exchange that Board of Directors at its meeting held on May 14, 2025, recommended Final Dividend of Rs. 12 per equity share i.e. 600 % of the Face Value of Rs. 2/ Each Fully Paid Up for the Financial Year Ended March 31, 2025.
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.3 pts less than Nifty Midcap 150 and 1.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Lupin's Board approved audited financial results for Q4 and FY ended March 31, 2025, alongside recommending a final dividend of Rs. 12 per share (600% on face value of Rs. 2), totalling Rs. 5,478.8 million, subject to shareholder approval at the AGM. Standalone revenue from operations grew 15.7% to Rs. 169,675 million while net profit jumped 70.8% to Rs. 39,729.6 million, pushing EPS to Rs. 87.10 from Rs. 51.10. Consolidated revenue rose 13.5% to Rs. 227,079 million and consolidated PAT climbed 70.8% to Rs. 33,062.6 million, with EPS at Rs. 71.95. The results include exceptional items of Rs. 772.2 million for impairment of investments in two subsidiaries, a Rs. 856.1 million (USD 10 million) provision for ongoing disputes, and a Rs. 750.5 million settlement related to the Glumetza litigation. The company is also transferring its OTC India business and API R&D business to wholly-owned subsidiaries on a slump sale basis.
Strong double-digit revenue growth and a sharp ~71% jump in profits reflect margin expansion and operational improvement, which should support the stock; the Rs. 12 dividend offers a healthy payout to shareholders awaiting AGM approval.